A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase of Trial: Phase II
Latest Information Update: 30 May 2019
Price : $35 *
At a glance
- Drugs Bermekimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors XBiotech
- 30 May 2019 According to a XBiotech media release, the company today announced that net proceeds of the public offering of common shares will be used primarily to advance bermekimab Phase 2 clinical trials in Hidradenitis Suppurativa.
- 05 Mar 2019 According to a XBiotech media release, results from the study were presented at the American Academy of Dermatology's annual meeting 2019.
- 05 Mar 2019 Results (n=42), presented in a XBiotech media release.